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Word count 3065 
Why was the cohort set up? 
Medical diagnostic examinations, although delivering low doses of ionizing radiation, are the main 
man-made source of ionizing radiation exposure for the general population. The number of 
procedures performed has grown dramatically in high income countries in recent decades.
1
 Among 
these examinations, computed tomography (CT) scanning, a highly informative medical imaging 
technique, has dramatically increased, partly as a result of the ease and speed of image acquisition 
improvements over years. These trends are also observed in paediatric CT scanning, which currently 
represents approximatively 11% of all CT examinations. 
1 
CT scanning results in much higher doses than conventional radiography. Indeed, CT scans represent 
5 to 10% of all imaging procedures, but 40 to 70% of the collective medical dose. 
1,2 
There are 
concerns about potential health impacts of the radiation exposure from these procedures, 
particularly cancer in exposed paediatric patients. According to the epidemiological results from A-
bomb survivors and from patients undergoing radiotherapy and/or radiological examinations, 
exposure to ionizing radiation at a young age is associated with a higher relative risk of several forms 
of cancer than exposure later in life.
3
 Moreover, children have a longer life expectancy than adults, 
and hence a longer time in which to express radiation induced cancers. 
Increased cancer risk has been reported after medical diagnostic procedures associated with much 
higher doses than those reported nowadays.
4,5
 However, recent epidemiological studies, focusing on 
CT scan exposure during childhood or early adulthood, have also reported increased risks of central 
nervous system (CNS) tumours, leukaemia, and other cancer types in relation to CT doses.
6-12
 The 
causal interpretation of some of these results has been questioned because of the lack of individual 
dose reconstruction, small sample size and potential methodological biases linked to confounding by 
indication and reverse causation.
13,14
  
Because the risk associated with low doses is estimated to be small
1
, only large studies can achieve 
adequate statistical power to quantify this risk accurately. The international “Epidemiological study 
to quantify risks for paediatric computerized tomography and to optimize doses” (EPI-CT) was set-up 
in 2011 to provide an estimation of the radiation-related risks of cancer after CT scan exposure in 
childhood and adolescence. The study is coordinated by the International Agency for Research on 
Cancer (IARC) and partially funded by the European Community. This European collaborative study 
pools nine European national cohorts. It takes advantage of pre-existing cohorts from three countries 
(France, Germany and the United Kingdom, all of which were extended as part of this study) and of 
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new studies in six countries based on a common core protocol
15
, including a specific effort to provide 
individual organ dose estimation for the subjects in the cohort.
16
 The EPI-CT study comprises four 
main parts: an epidemiological cohort study assessing cancer risks following radiation exposure from 
CT; a dose-reconstruction model to estimate organ doses with associated uncertainties for each 
individual in the cohort; a pilot study regarding biological mechanisms involved
17
; recommendations 
for optimization of paediatric CT protocols. 
Who is in the cohort? 
EPI-CT is a retrospective European multinational cohort of children and young adults subjected to at 
least 1 CT scan before the age of 22 years and who have not been diagnosed with cancer neither 
before nor at the time of the first recorded CT nor within 1 year after it. The study aimed to establish 
or expand existing cohorts in the following countries: Belgium, Denmark, France, Germany, the 
Netherlands, Norway, Spain, Sweden, and the United Kingdom (Table 1). Patients were identified 
from the electronic records of the participating hospitals, which were mainly large paediatric 
hospitals or hospitals with a large paediatric patient population. Ethical agreements were obtained in 
each country, prior to data collection. The study protocol
15
 and detailed procedures adopted by each 
country are described elsewhere.
6,9,10,12,18 
Of the 1,170,186 patients for whom information was collected, 948,174 (81%) had a follow-up of at 
least 1 year after the first recorded CT scan and had no previous cancer recorded in the cancer 
registry (Table 1). Table 2 summarizes the number and characteristics of patients included in EPI-CT 
by country. There were slightly more males (56%) than females in the cohort. The median age at the 
first CT recorded scan varied between countries, reflecting differences in the age-range inclusion 
criteria. While the main age range was 0-21 years, the age range was restricted to 0-9 and 0-14, 
respectively in France and Germany because only paediatric and adolescent cancer registries are 
available at the national level in these countries. Accordingly, the median age at first exposure was 
lower, 2.9 years old and 6.8 respectively, in France and Germany, compared to 10.7 years for the 
whole cohort.  
How have they been followed up? 
Follow-up started at the date of the first recorded CT scan and ended at the earliest of date of death, 
date of cancer diagnosis, or end of follow-up at the regional/national level. Cancer diagnoses and 
deaths were obtained through linkage with national or regional cancer registries, mortality registries 
and other available national/regional registries, depending on the country (Table1). The follow-up 
period for cancer incidence ends usually 1 to 3 years before mortality follow-up due to the delay in 
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reporting cancer cases in cancer registries. In two countries, vital status was partially (France) or 
completely unavailable (Germany). 
The earliest year of first recorded CT scan varied between 1977 in Sweden and 2001 in Belgium, and 
depended on the availability of data, i.e. complete cancer registration to exclude ineligible patients 
and electronic radiological information. Cancer incidence follow-up ended in 2014 in the Netherlands 
and Sweden, and between 2010 and 2013 in all other countries (Table 3). Median duration of 
incidence follow up was 7.8 years for the whole cohort, ranging from 4.1 years in Belgium to 11.3 
years in the UK (Table 3). The total incidence follow-up accounted for more than 8.7 million person-
years (PY). The largest cohorts in terms of PYs were the UK (3.7 million PY), the Dutch (1.5 million PY) 
and the Swedish cohorts (1.4 million PY) due to the large number of children included, but also due 
to the long follow-up. Only 1.3% of the participants had died by the end of follow-up. The median age 
at the end of follow-up ranged from 9.4 years in France to 24 years in the UK.  
What has been measured? 
For each individual CT scan, all computerized data were retrieved from the Radiological Information 
System (RIS) of the radiology department in participating hospitals. This includes patient identifying 
information, sex, date of birth, and basic variables about the examination (body part scanned, 
examination date and, in certain instances, indication for CT scan and referring hospital service). For 
more recent time-periods, estimation of doses took advantage of data from the Picture Archiving 
and Communication System (PACS) (a system for storage, retrieval and distribution of images). The 
time periods when PACS data were available together with the percentage of CT scan dosimetric 
data extracted from PACS for each country are presented in Table 4. The percentage of data 
originating from the PACS system, extracted through a dedicated software tool, PerMoS
19
 used to 
automatically collect technical parameters of each scan from the header of the image in PACS, 
differed between the countries since the system was only implemented relatively recently in 
hospitals and not all participating hospitals were willing to query their PACS in addition to RIS.  
From a combination of PACS data and information on radiological protocols used in the 
participating hospitals, individual doses to specific relevant organs, including red bone marrow and 
brain for respectively leukaemia and CNS cancer risk estimation, were then estimated for each CT 
scan for each child using NCICT software
20
, taking into account uncertainties in dose estimates.
16
 The 
dose reconstruction strategy which has been implemented allows accounting for missing data. 
Doses were therefore reconstructed for all examinations but estimated doses were associated with 
large uncertainties when examinations were poorly characterized in the RIS data file, including 
missing information on the anatomical zone scanned. The total number of CT scans collected within 
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the study was 1,430,454. The mean number of CT scans per patient was 1.5. The majority of patients 
(75%) received a single recorded CT scan (Table 4) while only 0.2% of them received more than 10 CT 
scans. The percentages of CT scans recorded before and after the year 2000 were 22% and 78%, 
respectively. Table 5 reports the distribution of CT scans according to the anatomical area explored. 
The main areas examined were “head and neck”, ranging from 49.5% in Denmark to 72.1% in 
Belgium, followed by “chest” accounting for 8.4% in Sweden to 19.3% in France. Scans of multiple 
body parts represented 4.9% of the total number of CT scans. Those without anatomical area 
mentioned represented 2.9% of all collected CT scans, with large discrepancies between countries 
reflecting the variability of data storage at hospital level.  
Further information on underlying diseases was also collected from various sources including hospital 
diagnostic or discharge databases and rare diseases registries (in France, the Netherlands, Norway, 
Spain, and Sweden). Socioeconomic status (SES), a potential confounder, was obtained from national 
census data by postal code or census track for Belgium, France, the Netherlands, Spain and the UK 
and from the National Education registry in Denmark, Norway and Sweden.  
What has been found? Key findings and publications 
Standardized Mortality Ratios (SMRs), as the ratio of observed and expected number of 
deaths based on national reference rates were calculated for the eight countries for which vital 
status was available, using a 1 year exclusion period. Results are presented (Table 6) for two distinct 
periods of follow-up after the first CT: year 2 to 5 and 5 years and beyond. The percentage of deaths 
varied from 0.5% in Belgium to 2.6% in the UK for the whole study period. Even though the death 
rates were low, we observed strongly elevated SMRs in all countries, especially in the first 5 years 
following the first CT scan (Table 6). The SMRs for all-cause mortality during the 5 years following the 
first CT scan were statistically significant and greater than 1 in all countries, varying from 1.9 in 
Belgium to 4.9 in  Denmark, France and the UK. For the time period greater than 5 years after the 
first CT scan, the SMR decreased, but remained significantly raised, in all countries except Belgium 
and Spain. Cancer mortality decreased to the level of the general population when time since first 
exposure exceeded 5 years, except in Sweden (SMR=1.3, 95% CI 1.1,1.6). However, non-cancer SMRs 
remained significantly increased when considering time since exposure greater than 5 years, except 
in France and Spain. These results illustrate the fact that, as expected, our study population was less 
healthy than the general population. Indeed, children undergoing CT scans, particularly those with 
repeated CT scans, are likely to suffer conditions that could be associated with increased mortality. 
The observed decrease of SMR for cancer when considering time since first CT scan greater than 5 
years confirms the need to apply exclusion periods in the statistical analyses to avoid reverse 
causation (i.e. the CT scan was performed because of a suspicion of cancer). Various exclusion 
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periods will be examined in the main risk analyses. Detailed dose-response analyses for cancer 
incidence will be presented in later papers. 
A summary of published results from national EPI-CT cohorts is provided in Table 7. Four 
national cohorts (the UK, France, Germany and the Netherlands) have published analyses of the 
relationship between CT scan exposure and cancer incidence. The British study reported a dose-
response relationship between CT scan-related dose and CNS tumours and leukaemia in exposed 
children and young adults
6,21
, but not for Hodgkin lymphoma.
22
 The German study reported a 
significantly increased incidence of cancer and lymphoma in exposed children compared to the 
general population.
9
 Both the French and the German studies, based on small numbers of cases, 
reported a dose-related increase for leukaemia and CNS tumours, though it was statistically 
significant only for CNS tumours in Germany.
9-11
 The Dutch study reported a dose-response 
relationship for cranial CNS tumours and found no association with leukemia.12 
Reverse causation bias has been considered by applying various exclusion periods for cancer 
risk analyses. Exclusion periods allowed accounting for individuals who were potentially scanned 
because of a suspicion of leukaemia (although CT scans generally are not required for the initial 
diagnosis of leukaemia) or CNS tumours, respectively. Extending the exclusion period from 5 to 10 
years for CNS tumours in the British study did not decrease the dose-risk estimates, as would be 
expected in case of reverse causation bias.
6 
Potential confounding by indication of a CT scan, meaning that children requiring CT scans 
may be at risk of cancer because of an underlying condition, has been handled in different manners 
in these studies. In the British study, an analysis published in 2016 took into account clinical 
information available in the RIS for 40% of the cohort and death certificates to evaluate this potential 
bias.
21
 This resulted in a slightly decreased, but still significant, dose-related increased risk for CNS 
tumours. Exclusion of previously unreported cancers reduced the Excess relative Risk (ERR) per mGy 
by 15% from 0.036 to 0.033 for leukaemia and by 30% from 0.023 to 0.016 for CNS tumours but 
these ERRs remained statistically significantly elevated. In the French cohort, using reliable 
information on predisposing factors (PF) for cancer from hospital discharge registries, 3% of the 
subjects were found to have a PF for CNS tumours and/or leukemia.
10
 This small percentage of 
individuals with PF was nevertheless much larger than expected in the general population.
23
 Separate 
analyses showed a dose-related increase of leukaemia and CNS tumours in children with no PFs while 
there was no evidence of an increase in those with PFs.
11
 The difference in radiation-related risks 
observed according to the presence of PFs might be explained by much higher mortality risks in 
patients having PFs compared to children without PF. Furthermore, Meulepas et al calculated the 
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magnitude of predisposing syndrome-related confounding of relative risk (RR) estimates for 
leukaemia and CNS tumours after diagnostic CT scans, under various assumptions for the association 
between predisposing syndromes and the frequency of CT scans. They concluded that these 
syndromes were unlikely to cause meaningful confounding as they were too rare and CT scan 
frequency was only moderately elevated among these subjects.
24 
What are the main strengths and weaknesses?  
With about 950,000 children included in the study, it has been calculated
14
 that the EPI-CT study has 
sufficient statistical power to detect even small excess cancer risks in this first follow-up period, at 
least for leukaemia and CNS cancer. It will provide new insights on the potential cancer risk from CT 
scan exposures during childhood, allowing the study of specific issues such as effect of age at 
exposure, sex, exclusion period and cancer site, particularly as the population ages and further 
follow-up is conducted. The coordinated international analyses in EPI-CT not only increase statistical 
power, but also improve capacity to compare and contrast results from different countries while 
minimizing methodological differences thanks to a common protocol. 
Within EPI-CT, major efforts were devoted to the estimation of individualized organ doses for each 
CT scan. Details are provided in the article presenting the dosimetry reconstruction for the cohort.
15
 
Briefly, exposure-related data were extracted from the RIS and, for more recent time-periods, from 
the PACS of participating hospitals, allowing examination-specific dose reconstructions. The 
implemented approach
15
 allows quantification of uncertainties in doses due to missing data and 
produces a range of potential doses for each CT scan, each set suitable for use in a dose-response as 
a surrogate of the true doses. Each missing parameter is represented by a probability density 
function (PDF) representative of the state of knowledge for the time period. For each calculation of 
the cohort dose set, values of parameters are selected from the appropriate PDFs while maintaining 
proper correlations between parameters. Recoding all examination types into one common 
classification, and centralized calculation of organ doses using the software NCI-CT
20
, with 
appropriately sized phantoms for paediatric age categories allowed a good standardization of the 
process. Apart from the use of doses for the main risk analysis, EPI-CT also provides the basis for a 
large and useful characterization of doses from CT scans in children in Europe, where previously only 
sparse information was available. 
A limitation of the study is the inability to contact almost one million individuals to collect more 
precise information on potential confounders such as underlying predisposing conditions, other 
medical radiation procedures performed in the hospital (nuclear medicine procedures, other X-rays) 
Page 9 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
or outside the participating hospitals. Indication for CT scanning is also not routinely recorded, and 
few countries have electronic medical record systems that could provide this information for a 
retrospective cohort of this type. Simulation studies based on scenarios of expected range of 
potential confounders based on information available in some of the participating countries or 
regions will be performed to provide information on the likelihood of missing data on the risks 
estimates. Sensitivity analyses will be performed on cohorts with information on potential 
confounders to provide a basis for adjusting risk estimates. Nested case-control studies are also 
being conducted in several countries (http://www.medirad-project.eu/) to allow collection of data on 
other radiation procedures, missing scans, predisposing factors and other potential confounders of 
the relation between CT dose and leukaemia and CNS tumour risks. 
Another limitation of the EPI-CT project is that the cohort is still relatively young, whereas many solid 
cancers (and non-cancer diseases) are more frequent at older ages. Further long-term follow-up of 
this important cohort will provide additional information and will allow a more precise quantification 
of the effects of exposure on different outcomes, as well as on the possible modifying effects of age 
at exposure and attained age on estimated risks. Supplementary funding should be provided to 
allow the long term follow-up. Additional follow-up is currently underway in 5 of the largest 
countries with funding from the European Union within the MEDIRAD project 
(http://www.medirad-project.eu). Funds will be sought in other countries to update the follow-up 
of the other cohorts in the coming years. 
 Can I get hold of the data? Where can I find out more? 
Study data are not freely available because of ethical and data protection constraints. The 
anonymized data are stored at the IARC and cannot be sent outside the Agency. Proposals for 
possible collaborations in further analyses of the data should be addressed to Dr Ausrele Kesminiene 
and will be reviewed by the EPI-CT steering committee. 
 
Profile in a Nutshell  
• The multinational EPI-CT study was set-up in 2011 to provide direct estimates of risk of solid 
tumours and leukaemia among children and young adults who underwent computed 
tomography (CT) scanning and to consolidate the scientific basis for optimization of 
paediatric CT protocols and patient protection. 
• Under a common protocol, cohort studies were conducted in Belgium, Denmark, France, 
Germany, the Netherlands, Norway, Spain, Sweden and the United Kingdom, coordinated by 
the International Agency for Research on Cancer (IARC).  
• The study recruited a total of about 950,000 patients having undergone at least one CT-scan 
before the age of 22 years. A total of 8.7 million person-years of incidence follow-up were 
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accrued between 1977 and 2014. Cohort members were followed up passively through 
linkage with population-based cancer and mortality registries. A methodology was developed 
to reconstruct individual organ doses and estimate associated uncertainties, using data 
available in electronic archiving systems of the radiology departments of participating 
hospitals. Description of the cohort and analysis of mortality risk are presented here. 
• Proposals for possible collaboration in further analyses of the data should be addressed to 
Dr. Ausrele Kesminiene (KesmienieneA@visitors.iarc.fr) and will be reviewed by the EPI-CT 
steering committee  
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Table 1: Description of the selection criteria and available data in the participating countries 
 Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Age range of patients at inclusion 0-18 0-18 0-9 0-14 0-17 0-20 0- 20 0-17 0-21 0-21 
Number of eligible patients at 
national level (1) 
14,002 21,649 121,101 63,998 158,130 80,225 171,336 128,748 410,997 1,170,186 
Exclusion  criteria 
          
   Inconsistent/incomplete data* 404 12 
     
4 111 531 
   Out of age range 
 
517 
   
15 
 
164 34 730 
   No CT scan in the follow-up 
period 
2,083 507 7 5,222 78 286 11,778 2,223 4,697 26,881 
   No cancer follow up 
      
60,860** 
 
51,837 112,697 
   Follow-up less than 1 year 1,074 1,666 1,611 6,607 3,962 1,103 12,072 1,564 16,973 46,632 
   Cancer diagnosed within 1 year   
after 1st CT scan 
367 1,251 84
 ±
 5,073 5,955 1,569 2,034 2,988 15,220 34,541 
Number of patients included in 
the international cohort (2) 
10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
(1)Initial number of patients included (before application of exclusion criteria); (2) Final number of eligible patients.*errors in date of birth, unknown date of cancer diagnosis; **in progress; 
 ±
 exclusion of 
patients with diagnostic of cancer within the first 6 months of follow-up at national level before sending the data for the pooled analysis. 
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Table2:  Distribution of study subjects by sex, country and age at the first CT examination  
Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Sex N (%) 
          
Male 
5,292 
(52.5) 
9,836 
(55.6) 
69,544 
(58.2) 
27,617 
(58.6) 
79,897 
(53.9) 
42,452 
(55.0) 
47,813 
(56.5) 
66,773 
(54.8) 
180,953 
(56.4 ) 
530,177 
(55.9) 
           
Female 
4,782 
(47.5) 
7,860 
(44.4) 
49,855 
(41.8) 
19,428 
(41.3) 
68,218 
(46.1) 
34,800 
(45.0) 
36,779 
(43.5) 
55,032 
(45.2) 
139,680 
(43.6) 
416,434 
(43.8) 
           
Unknown 
   
51 
(0.1) 
20 
(0)    
1,492 
(0.5) 
1,563 
(0.2) 
Median (mean) age, in years, at first examination 
     
Median 
(mean) 
11.5 
(10.4) 
12.9 
(11.3) 
2.9 
(3.5) 
6.8 
(6.8) 
11.5 
(10.3) 
14.5 
(12.8) 
13.5 
(12.0) 
11.3 
(10.3) 
13.5 
(12.0) 
10.7 
(10.2) 
Age at first CT examination N (%) 
       
<1 year 
831 
(8.2) 
1,340 
(7.6) 
34,732 
(29.1) 
5,590 
(11.9) 
13,752            
(9.3) 
4,118 
(5.3) 
6,377 
(7.5) 
9,723 
(8.0) 
32,873 
(10.2) 
109,33 
(11.5) 
           
1-4 years 
1,717 
(17.0) 
2,262 
(12.8) 
47,056 
(39.4) 
12,938 
(27.5) 
21,034 
(14.2) 
7,291 
(9.4) 
10,949 
(12.9) 
15,754 
(12.9) 
42,128 
(13.1) 
161,129 
(17.0) 
           
5-9 years 
1,824 
(18.1) 
2,820 
(15.9) 
37,611 
(31.5) 
14,171 
(30.1) 
28,997 
(19.6) 
11,156 
(14.4) 
13,216 
(15.6) 
26,600 
(21.8) 
43,515 
(13.5) 
179,910 
(19.0) 
           
10-19 years 
5,702 
(56.6) 
11,274 
(63.7)  
14,397 
(30.6) 
84,352 
(56.9) 
51,074 
(66.1) 
47,576 
(56.2) 
69,728 
(57.2) 
158,637 
(49.2) 
442,740 
(46.7) 
           
>= 20 years 
     
3,613 
(4.7) 
6,474 
(7.7)  
44,972 
(14.0) 
55,059 
(5.8) 
Total by 
country 
10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
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Table 3: Follow-up of the cohort 
 Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Mortality 
follow-up 
period 2001-2015 1999-2015 2000-2013  1979-2015 1980-2013 1991-2014 1977-2014 1985-2015 1977-2015 
Total of 
Person-Years 66,002 138,046 458,298 0 1,620,981 614,360 607,557 1,396,397 4,186,666 9,088,308 
Vital status  
N (%)           
Alive 
10,033 
(99.6) 
17,413 
(98.4) 
75,483 
(63.2) 
0 
(0) 
146,910 
(99.2) 
76,109 
(98.5) 
84,199 
(99.5) 
116,276 
(95.5) 
307,826 
(95.6) 
834,249 
(88.0) 
Deceased 
41 
(0.4) 
134 
(0.8) 
558 
(0.5) 
0 
(0) 
1,225 
(0.8) 
673 
(0.9) 
393 
(0.5) 
1,568 
(1.3) 
7,565 
(2.3) 
12,157 
(1.3) 
Lost to follow-
up 
0 
(0) 
149 
(0.8) 
0 
(0) 
0 
(0) 
0 
(0) 
470 
(0.6) 
0 
(0) 
3,961 
(3.3) 
6,734 
(2.1) 
11,314 
(1.2) 
Unavailable 
0 
(0) 
0 
(0) 
43,358 
(36.3) 
47,096 
(100) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
90,454 
(9.5) 
Cancer 
incidence 
follow-up 
period* 2001-2012 1999-2013 2000-2013 1980-2010 1979-2014 1980-2012 1991-2013 1977-2014 1985-2013 1977-2014 
 
Median 
(mean) age at 
end of follow-
up (years) 
16.2 
(15.1) 
18.1 
(17.1) 
9.4 
(9.3) 
14.2 
(12.2) 
20.1 
(20.4) 
21.2 
(20.8) 
18.4 
(17.3) 
21.7 
(21.7) 
24.0 
(23.6) 
19.5 
(19.5) 
Median 
duration of 
(mean)  
follow-up 4.1 5.3 5.4 4.7 8.2 6.8 4.8 10.3 11.3 7.8 
 (4.7) (5.8) (5.7) (5.4) (10.2) (7.9) (5.3) (11.4) (11.6) (9.3) 
Total of 
Person-years 47,815 102,657 685,333 252,970 1,506,728 613,390 448,475 1,393,454 3,720,888 8,771,710 
*: shorter follow-up period for cancer incidence compared to mortality follow-up period is linked to the delay of cancer registries to 
report cancer cases (availability of cancer cases 1 to 3 years after the cancer diagnosis date)     
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Table 4: Number of CT scans received by child 
Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Period with available PACS data (% of CT*) 
        
 
2001-2004 
(68) 
2005-2013 
(10) 
2003-2014 
(10) 
1995-2013  
(95) 
1991-2014  
(48) 
2000-2014 
(37) 
2000-2015 
(64) 
1998-2014 
(9) 
2000-2014  
(17) 
1991-2015  
(25) 
No of CT scans 
performed per child (%) 
          
1 CT scan 7,788 (77.3) 11,531 (65.2) 92,841 (77.8) 35,529 (75.4) 113,272 (76.5) 50,779 (65.7) 65,765 (77.7) 89,931 (73.8) 247,424 (76.8) 714,860 (75.4) 
           
2 CT scans 1,465 (14.5) 3,125 (17.7) 15,929 (13.3) 6,652 (14.1) 21,576 (14.6) 14,073 (18.2) 11,722 (13.9) 19,460 (16.0) 45,825 (14.2) 139,827 (14.7) 
           
3 CT scans 410 (4.1) 1,284 (7.3) 5,300 (4.4) 2,258 (4.8) 6,458 (4.4) 5,000 (6.5) 3,451 (4.1) 5,835 (4.8) 13,478 (4.2) 43,474 (4.6) 
           
4 CT scans+ 411 (4.1) 1,756 (9.9) 5,329 (4.5) 2,657 (5.6) 6,829 (4.6) 7,400 (9.6) 3,654 (4.3) 6,579 (5.4) 15,398 (4.8) 50,013 (5.3) 
           
Total 10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
*: proportion of CTs extracted from PACS of all CTs 
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Table 5 Distribution of CT scans according to age, calendar period and scanned region by  countries 
 Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Category of age at CT scan N (%) 
0-4 years 
 
3,457 
(24.3) 
6,127 
(18.6) 
115,857 
(67.5) 
27,031 
(37.8) 
51,127 
(23.5) 
18,767 
(13.4) 
24,754 
(20.4) 
37,223 
(20.1) 
112,135 
(23.6) 
396,478 
(27.7) 
           
5-9 years 
 
2,486 
(17.5) 
5,422 
(16.4) 
55,794 
(32.5) 
22,011 
(30.8) 
42,157 
(19.4) 
17,988 
(12.9) 
18,630 
(15.4) 
37,547 
(20.2) 
66,702 
(14.0) 
268,737 
(18.8) 
           
10-14 years 
 
3,554 
(25.0) 
9,498 
(28.8) 
45 
(0) 
22,517 
(31.5) 
61,985 
(28.5) 
29,527 
(21.2) 
25,597 
(21.1) 
59,665 
(32.2) 
95,744 
(20.1) 
308,132 
(21.5) 
           
>= 15 
 
4,707 
(33.1) 
11,959 
(36.2) 
0 
 
0 
 
62,530 
(28.7) 
73,281 
(52.5) 
52,132 
(43.0) 
51,025 
(27.5) 
201,473 
(42.3) 
457,107 
(32.0) 
Number of CT scans by calendar period N (%) 
Before 1985  
0 
 
0 
 
0 
 
77 
(0.1) 
3,377 
(1.6) 
703 
(0.5) 
0 
 
1,244 
(0.7) 
0 
 
5,401 
(0.4) 
           
1985-1999  
0 
 
11 
(0) 
0 
 
15,414 
(21.5) 
45,539 
(20.9) 
18,843 
(13.5) 
2,236 
(1.8) 
48,905 
(26.4) 
177,118 
(37.2) 
308,066 
(21.5) 
           
2000-2009  
10,174 
(71.6) 
20,514 
(62.2) 
130,676 
(76.1) 
55,178 
(77.1) 
112,675 
(51.7) 
95,336 
(68.3) 
81,529 
(67.3) 
101,159 
(54.5) 
252,552 
(53.1) 
859,793 
(60.1) 
           
>=2010  
 
4,030 
(28.4) 
12,481 
(37.8) 
41,020 
(23.9) 
890 
(1.2) 
56,208 
(25.8) 
24,681 
(17.7) 
37,348 
(30.8) 
34,152 
(18.4) 
46,384 
(9.7) 
257,194 
(18.0) 
Number of CT scans by 
anatomical region N (%) 
Head and 
neck 
10,248 
(72.1) 
16,332 
(49.5) 
117,458 
(68.4) 
50,854 
(71.1) 
152,690 
(70.1) 
80,562 
(57.7) 
77,082 
(63.6) 
118,684 
(64.0) 
319,430 
(67.1) 
943,340 
(65.9) 
           
Chest 
1,298 
(9.1) 
4,342 
(13.2) 
33,108 
(19.3) 
8,225 
(11.5) 
18,543 
(8.5) 
19,132 
(13.7) 
11,148 
(9.2) 
15,529 
(8.4) 
40,244 
(8.5) 
151,569 
(10.6) 
           
Abdomen and 1,820 5,356 8,329 4,042 21,231 27,396 5,965 31,130 45,037 150,306 
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pelvis (%) (12.8) (16.2) (4.9) (5.6) (9.7) (19.6) (4.9) (16.8) (9.5) (10.5) 
           
Extremities 
(%) 
664 
(4.7) 
3,364 
(10.2) 
2,590 
(1.5) 
2,589 
(3.6) 
16,719 
(7.7) 
9,784 
(7.0) 
6,379 
(5.3) 
8,221 
(4.4) 
23,160 
(4.9) 
73,470 
(5.1) 
           
Multiple 
(%) 
139 
(1.0) 
3,269 
(9.9) 
8,592 
(5.0) 
3,716 
(5.2) 
5,880 
(2.7) 
2,342 
(1.7) 
8,166 
(6.7) 
7,559 
(4.1) 
30,184 
(6.3) 
69,847 
(4.9) 
Not classified 
35 
(0.2) 
343 
(1.0) 
1,619 
(0.9) 
2,133 
(3.0) 
2,736 
(1.3) 
347 
(0.2) 
12,373 
(10.2) 
4,337 
(2.3) 
17,999 
(3.8) 
41,922 
(2.9) 
Total 14,204 33,006 171,696 71,559 217,799 139,563 121,113 185,460 476,054 1,430,454 
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Table 6: SMRS of all cause, cancer and non-cancer mortality according to the time since the first CT (< 5 years; >= 5 years) 
  Time since first CT scan recorded 
 
1-5 yrs   > 5 yrs 
  
All causes 
mortality 
All cancer  
mortality 
Non cancer 
mortality  
All causes  
mortality 
All cancer  
mortality 
Non cancer  
mortality 
 
PY O  SMR (95% CI) O  SMR (95% CI) O  SMR (95% CI) PY O  SMR (95% CI) O  SMR (95% CI) O  SMR (95% CI) 
Belgium 48,125  26 1.9 (1.2,2.8)   -   - 53,387 22 1.4 (0.9,2.2)   -   - 
Denmark   84,443 101 4.9 (4.0,5.9)  - - 120,984 73 2.4 (1.9,3.1) - - 
France 322,247 474 4.9 (4.4,5.3) 25 3.5 (2.3,5.1) 357 4.0 (3.6,4.4)  349,971 120  1.6 (1.3,1.9) 6 0.8 (0.3,1.6) 79 1.1 (0.9,1.4) 
Netherlands  
693,933  692 3.7 (3.4,3.9) - - 
 
1,507,572 580  1.2 (1.1,1.3) 
 
- 
 
- 
Norway  334,723 332 2.8 (2.5,3.1) 14 1.3 (0.7,2.2) 296 2.7 (2.4,3.0)  535,107 416  1.8 (1.6,2.0) 28 1.1 (0.7,1.5) 331 1.6 (1.5,1.8) 
Spain 391,219 361 3.4 (3.1,3.8) 89 6.1 (4.9,7.5) 272 3.0 (2.6,3.4) 521,598 167  1.1 (1.0,1.3) 19 0.9 (0.5,1.3) 148 1.2 (1.0,1.4) 
Sweden 
 573,367 506 3.3 (3.0,3.6) 
58 
3.3 (2.5,4.3) 446 3.3 (3.0,3.6) 
 
1,318,489 1062 2.3 (2.2,2.4) 85 
1.3 (1.1,1.7) 
975 2.4 (2.3,2.6) 
UK 1,563,679 3068 4.9 (4.8,5.1) 177 3.0 (2.5,3.4) 2286 4.1 (3.9,4.3) 4,059,802 5,233  2.7 (2.6,2.7) 326 1.1 (1.0,1.2) 4200 2.5 (2.4,2.6) 
Pooled 4,011,736 5560 4.2 (4.1,4.3) 363 3.3 (3.0,3.7) 3657 3.7 (3.6,3.8) 8,466,910 7,673 2.2 (2.2,2.3) 464 1.1 (1.0,1.2) 5733 2.3 (2.3,2.4) 
PYs: Person-Years of follow-up; O: observed cases within the cohort; SMR: Standardized Mortality Ratio; 95% CI: 95% Confidence Interval. -: cause of death unknown; 
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Table 7: Results from EPI-CT national cohorts   
Outcome Country Cases Risk estimates (IC 95%) 
      CNS tumour risk according 
to the brain dose     
 
UK
±
 (Pearce et al, 2012) 135* ERR per mGy 0.023 (0.010,0.049) 
 
UK
±
  (Berrington et al, 2016) 122* without PF ERR per mGy 0.019 (0.008,0.043) 
 
France (Journy et al, 2015) 22 ERR per mGy 0.022  (-0.016,0.061) 
 
The Netherlands (Meulepas et al, 2018) 84 ERR per mGy 0.0086 (0.0020,0.022) 
 
Germany (Krille et al, 2015) 7 HR per mGy 1.008 (1.00,1.01) 
     
 
France (Journy et al, 2016) 15 without PF HR per 10 mGy  1.07 (0.99,1.10) 
  
7 with PF HR per 10 mGy 0.8 (0.45,1.06) 
 
UK
±
  (Pearce et al, 2012) 135* RR [50-74 mGy] vs < 5 mGy 2.82 
(1.34,6.03) 
     
Leukaemia risk according 
to RBM dose     
 
UK
±
  (Pearce et al, 2012) 74 ERR per mGy (RBM dose) 0.036 (0.005,0.120) 
 
France (Journy et al, 2015) 17 ERR per mGy 0.057 (-0.079,0.193) 
 
The Netherlands (Meulepas et al, 2018) 44 ERR per mGy 0.0004 (-0.0012,0.016) 
 
UK
±
  (Berrington et al, 2016) 70 without PF ERR per mGy 0.037 (0.005,0.126) 
     
 
France (Journy et al, 2016) 12 without PF HR per 10 mGy 1.16 (0.77-1.27) 
France (Journy et al, 2016) 5 with PF HR per 10 mGy 0.57 (0.06,1.32) 
 
Germany (Krille et al, 2015) 17 HR per mGy 1.009 (0.98,1.04) 
 
UK (Pearce et al, 2012) 74 RR [>30 mGy] vs < 5 mGy 3.18 
(1.46,6.94) 
     
 Lymphoma risk according 
to RBM dose 
 
France (Journy et al, 2015) 19 ERR per mGy 0.018 (-0.068,0.104) 
  UK
±
  (Berrington et al, 2017) 65** RR [> 20] vs <5 mGy 0.92 (0.22,2.94) 
CNS: Central Nervous System; PF: predisposing factor to CNS tumor or leukaemia, accordingly; RBM: Red Bone Marrow; ERR: Excess Relative Risk; RR: Relative Risk; HR: Hazard Ratio; mGy: milligray;  
UK: United Kingdom; * Exclusion period 5 years instead of 2 years; **: Hodgkin lymphoma only;
 ±: 
follow-up period until 2005 only. 
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Title :Cohort Profile: The EPI-CT study: a European pooled epidemiological study to quantify the 
potential radiation-induced risks associated to paediatric CT-scans 
List of authors
*
: 
Marie-Odile Bernier
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, Mark S Pearce
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, Elisabeth Cardis
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, Michael Hauptmann
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, Lara Struelens
5
, 
Christoffer Johansen
6
, Maria Blettner
7
, Kristina Kjaerheim
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, Magnus Kaijser
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, Ausrele Kesminiene
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on 
the behalf of the EPI-CT consortium.  
*: the complete list of the authors is available in the full version of the profile 
Keywords: cohort study, ionizing radiation; paediatrics; cancer; 
For correspondence: Marie-Odile Bernier; marie-odile.bernier@irsn.fr. 
The full version of this profile is available at IJE online and should be used when citing this profile. 
Cohort purpose: 
There are concerns about potential health impacts of ionizing radiation exposure from computed 
tomography (CT) procedures, delivering much higher doses than conventional radiography. Children 
are of particular interest since they are more at risk for radiation-induced cancer and have a long life 
expectancy.  
The international “Epidemiological study to quantify risks for paediatric computerized tomography 
and to optimize doses” (EPI-CT), coordinated by the International Agency for Research on Cancer 
(IARC), was set-up in 2011 to provide an estimation of the radiation-related risks of cancer after CT 
scan exposure in childhood and adolescence. 
Cohort basics: 
EPI-CT is a retrospective European multinational cohort of 948,174 patients subjected to at least 1 CT 
scan before the age of 22 years and who were free of cancer 1 year after the first recorded CT in the 
following countries: Belgium, Denmark, France, Germany, the Netherlands, Norway, Spain, Sweden, 
and the United Kingdom. The median age at first exposure was 10.7 years.  
Follow-up and attrition: 
The earliest year of first recorded CT scan varied between 1977 in Sweden and 2001 in Belgium. 
Cohort members were followed up passively through linkage with population-based cancer and 
mortality registries until 2014. Median duration of follow up was 7.8 years. The total incidence 
follow-up accounted for more than 8.7 million person-years.  By the end of follow-up, 1.3% of the 
participants had died.  
Design and Measures: 
Reconstruction of individual organ doses was performed using data available in electronic archiving 
systems of the radiology departments of participating hospitals for the 1,430,454T CT scans 
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collected. The majority of patients (75%) received a single CT scan while 0.2% received more than 10 
CT scans. 
Unique features: 
Standardized Mortality Ratios (SMRs) from all causes, cancer and non-cancer during the 5 
years following the first CT scan were statistically increased in all countries. Indeed, children 
undergoing CT scans, particularly those with repeated CT scans, are likely to suffer conditions that 
could be associated with increased mortality. SMR for cancer decreased when restricting analyses to 
subjects who survived at least 5 years after the first CT confirming the need to apply exclusion 
periods in the analyses to avoid reverse causation. Dose-response analyses for cancer incidence will 
be presented in later papers. 
Reasons to be cautious: 
Potential confounders of the relation between CT dose and leukaemia and CNS tumour risks such as 
underlying predisposing conditions, other medical radiation procedures performed in or outside the 
participating hospitals should be studied. Sensitivity analyses on cohorts with available information 
on potential confounders and nested case-control studies in some countries are being conducted to 
address this issue (http://www.medirad-project.eu/). 
Collaboration and data access:  
Proposals for possible collaboration in further analyses should be addressed to Dr. Ausrele 
Kesminiene (KesmienieneA@visitors.iarc.fr) and will be reviewed by the EPI-CT steering committee 
Funding and competing interests 
National cohorts were partially funded by national or international funds, but also (except the 
Norwegian cohort) by the European Union’s Seventh Program for research, technological 
development and demonstration under Grant Agreement No 269912—EPI-CT. No competing 
interests. 
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Roses, France 
2: Institute of Health & Society, Newcastle University, Newcastle upon Tyne, UK 
3: IARC, Lyon, France 
4: Barcelona Institute for Global Health ISGlobal, ISGlobal, Spain 
5: Netherlands Cancer Institute, Amsterdam, The  Netherlands 
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Table2:  Distribution of eligible study subjects by sex, country and age at the first CT examination  
Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Sex N (%) 
          
Male 
5,292 
(52.5) 
9,836 
(55.6) 
69,544 
(58.2) 
27,617 
(58.6) 
79,897 
(53.9) 
42,452 
(55.0) 
47,813 
(56.5) 
66,773 
(54.8) 
180,953 
(56.4 ) 
530,177 
(55.9) 
           
Female 
4,782 
(47.5) 
7,860 
(44.4) 
49,855 
(41.8) 
19,428 
(41.3) 
68,218 
(46.1) 
34,800 
(45.0) 
36,779 
(43.5) 
55,032 
(45.2) 
139,680 
(43.6) 
416,434 
(43.8) 
           
Unknown 
   
51 
(0.1) 
20 
(0)    
1,492 
(0.5) 
1,563 
(0.2) 
Age at first CT examination N (%) 
       
<1 year 
831 
(8.2) 
1,340 
(7.6) 
34,732 
(29.1) 
5,590 
(11.9) 
13,752            
(9.3) 
4,118 
(5.3) 
6,377 
(7.5) 
9,723 
(8.0) 
32,873 
(10.2) 
109,33 
(11.5) 
           
1-4 years 
1,717 
(17.0) 
2,262 
(12.8) 
47,056 
(39.4) 
12,938 
(27.5) 
21,034 
(14.2) 
7,291 
(9.4) 
10,949 
(12.9) 
15,754 
(12.9) 
42,128 
(13.1) 
161,129 
(17.0) 
           
5-9 years 
1,824 
(18.1) 
2,820 
(15.9) 
37,611 
(31.5) 
14,171 
(30.1) 
28,997 
(19.6) 
11,156 
(14.4) 
13,216 
(15.6) 
26,600 
(21.8) 
43,515 
(13.5) 
179,910 
(19.0) 
           
10-19 years 
5,702 
(56.6) 
11,274 
(63.7)  
14,397 
(30.6) 
84,352 
(56.9) 
51,074 
(66.1) 
47,576 
(56.2) 
69,728 
(57.2) 
158,637 
(49.2) 
442,740 
(46.7) 
           
>= 20 years 
     
3,613 
(4.7) 
6,474 
(7.7)  
44,972 
(14.0) 
55,059 
(5.8) 
Total by 
country 
10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
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Word count 3065 
Why was the cohort set up? 
Medical diagnostic examinations, although delivering low doses of ionizing radiation, are the main 
man-made source of ionizing radiation exposure for the general population. The number of 
procedures performed has grown dramatically in high income countries in recent decades.
1
 Among 
these examinations, computed tomography (CT) scanning, a highly informative medical imaging 
technique, has dramatically increased, partly as a result of the ease and speed of image acquisition 
improvements over years. These trends are also observed in paediatric CT scanning, which currently 
represents approximatively 11% of all CT examinations. 
1 
CT scanning results in much higher doses than conventional radiography. Indeed, CT scans represent 
5 to 10% of all imaging procedures, but 40 to 70% of the collective medical dose. 
1,2 
There are 
concerns about potential health impacts of the radiation exposure from these procedures, 
particularly cancer in exposed paediatric patients. According to the epidemiological results from A-
bomb survivors and from patients undergoing radiotherapy and/or radiological examinations, 
exposure to ionizing radiation at a young age is associated with a higher relative risk of several forms 
of cancer than exposure later in life.
3
 Moreover, children have a longer life expectancy than adults, 
and hence a longer time in which to express radiation induced cancers. 
Increased cancer risk has been reported after medical diagnostic procedures associated with much 
higher doses than those reported nowadays.
4,5
 However, recent epidemiological studies, focusing on 
CT scan exposure during childhood or early adulthood, have also reported increased risks of central 
nervous system (CNS) tumours, leukaemia, and other cancer types in relation to CT doses.
6-12
 The 
causal interpretation of some of these results has been questioned because of the lack of individual 
dose reconstruction, small sample size and potential methodological biases linked to confounding by 
indication and reverse causation.
13,14
  
Because the risk associated with low doses is estimated to be small
1
, only large studies can achieve 
adequate statistical power to quantify this risk accurately. The international “Epidemiological study 
to quantify risks for paediatric computerized tomography and to optimize doses” (EPI-CT) was set-up 
in 2011 to provide an estimation of the radiation-related risks of cancer after CT scan exposure in 
childhood and adolescence. The study is coordinated by the International Agency for Research on 
Cancer (IARC) and partially funded by the European Community. This European collaborative study 
pools nine European national cohorts. It takes advantage of pre-existing cohorts from three countries 
(France, Germany and the United Kingdom, all of which were extended as part of this study) and of 
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new studies in six countries based on a common core protocol
15
, including a specific effort to provide 
individual organ dose estimation for the subjects in the cohort.
16
 The EPI-CT study comprises four 
main parts: an epidemiological cohort study assessing cancer risks following radiation exposure from 
CT; a dose-reconstruction model to estimate organ doses with associated uncertainties for each 
individual in the cohort; a pilot study regarding biological mechanisms involved
17
; recommendations 
for optimization of paediatric CT protocols. 
Who is in the cohort? 
EPI-CT is a retrospective European multinational cohort of children and young adults subjected to at 
least 1 CT scan before the age of 22 years and who have not been diagnosed with cancer neither 
before nor at the time of the first recorded CT nor within 1 year after it. The study aimed to establish 
or expand existing cohorts in the following countries: Belgium, Denmark, France, Germany, the 
Netherlands, Norway, Spain, Sweden, and the United Kingdom (Table 1). Patients were identified 
from the electronic records of the participating hospitals, which were mainly large paediatric 
hospitals or hospitals with a large paediatric patient population. Ethical agreements were obtained in 
each country, prior to data collection. The study protocol
15
 and detailed procedures adopted by each 
country are described elsewhere.
6,9,10,12,18 
Of the 1,170,186 patients for whom information was collected, 948,174 (81%) had a follow-up of at 
least 1 year after the first recorded CT scan and had no previous cancer recorded in the cancer 
registry (Table 1). Table 2 summarizes the number and characteristics of patients included in EPI-CT 
by country. There were slightly more males (56%) than females in the cohort. The median age at the 
first CT recorded scan varied between countries, reflecting differences in the age-range inclusion 
criteria. While the main age range was 0-21 years, the age range was restricted to 0-9 and 0-14, 
respectively in France and Germany because only paediatric and adolescent cancer registries are 
available at the national level in these countries. Accordingly, the median age at first exposure was 
lower, 2.9 years old and 6.8 respectively, in France and Germany, compared to 10.7 years for the 
whole cohort.  
How have they been followed up? 
Follow-up started at the date of the first recorded CT scan and ended at the earliest of date of death, 
date of cancer diagnosis, or end of follow-up at the regional/national level. Cancer diagnoses and 
deaths were obtained through linkage with national or regional cancer registries, mortality registries 
and other available national/regional registries, depending on the country (Table1). The follow-up 
period for cancer incidence ends usually 1 to 3 years before mortality follow-up due to the delay in 
Page 30 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
reporting cancer cases in cancer registries. In two countries, vital status was partially (France) or 
completely unavailable (Germany). 
The earliest year of first recorded CT scan varied between 1977 in Sweden and 2001 in Belgium, and 
depended on the availability of data, i.e. complete cancer registration to exclude ineligible patients 
and electronic radiological information. Cancer incidence follow-up ended in 2014 in the Netherlands 
and Sweden, and between 2010 and 2013 in all other countries (Table 3). Median duration of 
incidence follow up was 7.8 years for the whole cohort, ranging from 4.1 years in Belgium to 11.3 
years in the UK (Table 3). The total incidence follow-up accounted for more than 8.7 million person-
years (PY). The largest cohorts in terms of PYs were the UK (3.7 million PY), the Dutch (1.5 million PY) 
and the Swedish cohorts (1.4 million PY) due to the large number of children included, but also due 
to the long follow-up. Only 1.3% of the participants had died by the end of follow-up. The median age 
at the end of follow-up ranged from 9.4 years in France to 24 years in the UK.  
What has been measured? 
For each individual CT scan, all computerized data were retrieved from the Radiological Information 
System (RIS) of the radiology department in participating hospitals. This includes patient identifying 
information, sex, date of birth, and basic variables about the examination (body part scanned, 
examination date and, in certain instances, indication for CT scan and referring hospital service). For 
more recent time-periods, estimation of doses took advantage of data from the Picture Archiving 
and Communication System (PACS) (a system for storage, retrieval and distribution of images). The 
time periods when PACS data were available together with the percentage of CT scan dosimetric data 
extracted from PACS for each country are presented in Table 4. The percentage of data originating 
from the PACS system, extracted through a dedicated software tool, PerMoS
19
 used to automatically 
collect technical parameters of each scan from the header of the image in PACS, differed between 
the countries since the system was only implemented relatively recently in hospitals and not all 
participating hospitals were willing to query their PACS in addition to RIS.  
From a combination of PACS data and information on radiological protocols used in the participating 
hospitals, individual doses to specific relevant organs, including red bone marrow and brain for 
respectively leukaemia and CNS cancer risk estimation, were then estimated for each CT scan for 
each child using NCICT software
20
, taking into account uncertainties in dose estimates.
16
 The dose 
reconstruction strategy which has been implemented allows accounting for missing data. Doses were 
therefore reconstructed for all examinations but estimated doses were associated with large 
uncertainties when examinations were poorly characterized in the RIS data file, including missing 
information on the anatomical zone scanned. The total number of CT scans collected within the 
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study was 1,430,454. The mean number of CT scans per patient was 1.5. The majority of patients 
(75%) received a single recorded CT scan (Table 4) while only 0.2% of them received more than 10 CT 
scans. The percentages of CT scans recorded before and after the year 2000 were 22% and 78%, 
respectively. Table 5 reports the distribution of CT scans according to the anatomical area explored. 
The main areas examined were “head and neck”, ranging from 49.5% in Denmark to 72.1% in 
Belgium, followed by “chest” accounting for 8.4% in Sweden to 19.3% in France. Scans of multiple 
body parts represented 4.9% of the total number of CT scans. Those without anatomical area 
mentioned represented 2.9% of all collected CT scans, with large discrepancies between countries 
reflecting the variability of data storage at hospital level.  
Further information on underlying diseases was also collected from various sources including hospital 
diagnostic or discharge databases and rare diseases registries (in France, the Netherlands, Norway, 
Spain, and Sweden). Socioeconomic status (SES), a potential confounder, was obtained from national 
census data by postal code or census track for Belgium, France, the Netherlands, Spain and the UK 
and from the National Education registry in Denmark, Norway and Sweden.  
What has been found? Key findings and publications 
Standardized Mortality Ratios (SMRs), as the ratio of observed and expected number of 
deaths based on national reference rates were calculated for the eight countries for which vital 
status was available, using a 1 year exclusion period. Results are presented (Table 6) for two distinct 
periods of follow-up after the first CT: year 2 to 5 and 5 years and beyond. The percentage of deaths 
varied from 0.5% in Belgium to 2.6% in the UK for the whole study period. Even though the death 
rates were low, we observed strongly elevated SMRs in all countries, especially in the first 5 years 
following the first CT scan (Table 6). The SMRs for all-cause mortality during the 5 years following the 
first CT scan were statistically significant and greater than 1 in all countries, varying from 1.9 in 
Belgium to 4.9 in  Denmark, France and the UK. For the time period greater than 5 years after the 
first CT scan, the SMR decreased, but remained significantly raised, in all countries except Belgium 
and Spain. Cancer mortality decreased to the level of the general population when time since first 
exposure exceeded 5 years, except in Sweden (SMR=1.3, 95% CI 1.1,1.6). However, non-cancer SMRs 
remained significantly increased when considering time since exposure greater than 5 years, except 
in France and Spain. These results illustrate the fact that, as expected, our study population was less 
healthy than the general population. Indeed, children undergoing CT scans, particularly those with 
repeated CT scans, are likely to suffer conditions that could be associated with increased mortality. 
The observed decrease of SMR for cancer when considering time since first CT scan greater than 5 
years confirms the need to apply exclusion periods in the statistical analyses to avoid reverse 
causation (i.e. the CT scan was performed because of a suspicion of cancer). Various exclusion 
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periods will be examined in the main risk analyses. Detailed dose-response analyses for cancer 
incidence will be presented in later papers. 
A summary of published results from national EPI-CT cohorts is provided in Table 7. Four 
national cohorts (the UK, France, Germany and the Netherlands) have published analyses of the 
relationship between CT scan exposure and cancer incidence. The British study reported a dose-
response relationship between CT scan-related dose and CNS tumours and leukaemia in exposed 
children and young adults
6,21
, but not for Hodgkin lymphoma.
22
 The German study reported a 
significantly increased incidence of cancer and lymphoma in exposed children compared to the 
general population.
9
 Both the French and the German studies, based on small numbers of cases, 
reported a dose-related increase for leukaemia and CNS tumours, though it was statistically 
significant only for CNS tumours in Germany.
9-11
 The Dutch study reported a dose-response 
relationship for cranial CNS tumours and found no association with leukemia.
12 
Reverse causation bias has been considered by applying various exclusion periods for cancer 
risk analyses. Exclusion periods allowed accounting for individuals who were potentially scanned 
because of a suspicion of leukaemia (although CT scans generally are not required for the initial 
diagnosis of leukaemia) or CNS tumours, respectively. Extending the exclusion period from 5 to 10 
years for CNS tumours in the British study did not decrease the dose-risk estimates, as would be 
expected in case of reverse causation bias.
6 
Potential confounding by indication of a CT scan, meaning that children requiring CT scans 
may be at risk of cancer because of an underlying condition, has been handled in different manners 
in these studies. In the British study, an analysis published in 2016 took into account clinical 
information available in the RIS for 40% of the cohort and death certificates to evaluate this potential 
bias.
21
 This resulted in a slightly decreased, but still significant, dose-related increased risk for CNS 
tumours. Exclusion of previously unreported cancers reduced the Excess relative Risk (ERR) per mGy 
by 15% from 0.036 to 0.033 for leukaemia and by 30% from 0.023 to 0.016 for CNS tumours but 
these ERRs remained statistically significantly elevated. In the French cohort, using reliable 
information on predisposing factors (PF) for cancer from hospital discharge registries, 3% of the 
subjects were found to have a PF for CNS tumours and/or leukemia.
10
 This small percentage of 
individuals with PF was nevertheless much larger than expected in the general population.
23
 Separate 
analyses showed a dose-related increase of leukaemia and CNS tumours in children with no PFs while 
there was no evidence of an increase in those with PFs.
11
 The difference in radiation-related risks 
observed according to the presence of PFs might be explained by much higher mortality risks in 
patients having PFs compared to children without PF. Furthermore, Meulepas et al calculated the 
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magnitude of predisposing syndrome-related confounding of relative risk (RR) estimates for 
leukaemia and CNS tumours after diagnostic CT scans, under various assumptions for the association 
between predisposing syndromes and the frequency of CT scans. They concluded that these 
syndromes were unlikely to cause meaningful confounding as they were too rare and CT scan 
frequency was only moderately elevated among these subjects.
24 
What are the main strengths and weaknesses?  
With about 950,000 children included in the study, it has been calculated
14
 that the EPI-CT study has 
sufficient statistical power to detect even small excess cancer risks in this first follow-up period, at 
least for leukaemia and CNS cancer. It will provide new insights on the potential cancer risk from CT 
scan exposures during childhood, allowing the study of specific issues such as effect of age at 
exposure, sex, exclusion period and cancer site, particularly as the population ages and further 
follow-up is conducted. The coordinated international analyses in EPI-CT not only increase statistical 
power, but also improve capacity to compare and contrast results from different countries while 
minimizing methodological differences thanks to a common protocol. 
Within EPI-CT, major efforts were devoted to the estimation of individualized organ doses for each 
CT scan. Details are provided in the article presenting the dosimetry reconstruction for the cohort.
15
 
Briefly, exposure-related data were extracted from the RIS and, for more recent time-periods, from 
the PACS of participating hospitals, allowing examination-specific dose reconstructions. The 
implemented approach
15
 allows quantification of uncertainties in doses due to missing data and 
produces a range of potential doses for each CT scan, each set suitable for use in a dose-response as 
a surrogate of the true doses. Each missing parameter is represented by a probability density 
function (PDF) representative of the state of knowledge for the time period. For each calculation of 
the cohort dose set, values of parameters are selected from the appropriate PDFs while maintaining 
proper correlations between parameters. Recoding all examination types into one common 
classification, and centralized calculation of organ doses using the software NCI-CT
20
, with 
appropriately sized phantoms for paediatric age categories allowed a good standardization of the 
process. Apart from the use of doses for the main risk analysis, EPI-CT also provides the basis for a 
large and useful characterization of doses from CT scans in children in Europe, where previously only 
sparse information was available. 
A limitation of the study is the inability to contact almost one million individuals to collect more 
precise information on potential confounders such as underlying predisposing conditions, other 
medical radiation procedures performed in the hospital (nuclear medicine procedures, other X-rays) 
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or outside the participating hospitals. Indication for CT scanning is also not routinely recorded, and 
few countries have electronic medical record systems that could provide this information for a 
retrospective cohort of this type. Simulation studies based on scenarios of expected range of 
potential confounders based on information available in some of the participating countries or 
regions will be performed to provide information on the likelihood of missing data on the risks 
estimates. Sensitivity analyses will be performed on cohorts with information on potential 
confounders to provide a basis for adjusting risk estimates. Nested case-control studies are also 
being conducted in several countries (http://www.medirad-project.eu/) to allow collection of data on 
other radiation procedures, missing scans, predisposing factors and other potential confounders of 
the relation between CT dose and leukaemia and CNS tumour risks. 
Another limitation of the EPI-CT project is that the cohort is still relatively young, whereas many solid 
cancers (and non-cancer diseases) are more frequent at older ages. Further long-term follow-up of 
this important cohort will provide additional information and will allow a more precise quantification 
of the effects of exposure on different outcomes, as well as on the possible modifying effects of age 
at exposure and attained age on estimated risks. Supplementary funding should be provided to allow 
the long term follow-up. Additional follow-up is currently underway in 5 of the largest countries with 
funding from the European Union within the MEDIRAD project (http://www.medirad-project.eu). 
Funds will be sought in other countries to update the follow-up of the other cohorts in the coming 
years. 
 Can I get hold of the data? Where can I find out more? 
Study data are not freely available because of ethical a d data protection constraints. The 
anonymized data are stored at the IARC and cannot be sent outside the Agency. Proposals for 
possible collaborations in further analyses of the data should be addressed to Dr Ausrele Kesminiene 
and will be reviewed by the EPI-CT steering committee. 
 
Profile in a Nutshell  
• The multinational EPI-CT study was set-up in 2011 to provide direct estimates of risk of solid 
tumours and leukaemia among children and young adults who underwent computed 
tomography (CT) scanning and to consolidate the scientific basis for optimization of 
paediatric CT protocols and patient protection. 
• Under a common protocol, cohort studies were conducted in Belgium, Denmark, France, 
Germany, the Netherlands, Norway, Spain, Sweden and the United Kingdom, coordinated by 
the International Agency for Research on Cancer (IARC).  
• The study recruited a total of about 950,000 patients having undergone at least one CT-scan 
before the age of 22 years. A total of 8.7 million person-years of incidence follow-up were 
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accrued between 1977 and 2014. Cohort members were followed up passively through 
linkage with population-based cancer and mortality registries. A methodology was developed 
to reconstruct individual organ doses and estimate associated uncertainties, using data 
available in electronic archiving systems of the radiology departments of participating 
hospitals. Description of the cohort and analysis of mortality risk are presented here. 
• Proposals for possible collaboration in further analyses of the data should be addressed to 
Dr. Ausrele Kesminiene (KesmienieneA@visitors.iarc.fr) and will be reviewed by the EPI-CT 
steering committee  
 
Funding 
The UK study was partially supported by US National Cancer Institute (NO2-CP-75501), Radiation 
Research Programme of the UK Department of Health (RRX119), Cancer Research UK 
(C22891/A16015) and NIHR Health Protection Research Unit in Chemical and Radiation Threats and 
Hazards (no Grant No.). 
The French study received funding from the French national Cancer Institute (Grant No 2011-1-PL-
SHS-01-IRSN-1) and from “la Ligue contre le cancer” (Grant No PRE09/MOB) 
The Dutch study was partially supported by Worldwide Cancer Research formelly known as 
Association for International Cancer Research (grant 12-1155). 
The German study was partially funded by the German Federal Ministry of Education and Research 
under grant numbers 02NUK016A, 02NUK016B and 02NUK016CX.  
The Norwegian cohort was funded by the Research Council of Norway. 
The Spanish study was partially supported by a grant from the Spanish Nuclear Safety Council 
(Consejo de Seguridad Nuclear). M. Bosch de Basea was the recipient of a fellowship of the Centro de 
Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP) for a short stay abroad 
at Newcastle University.  
 
All the national cohorts (except the Norwegian cohort) were funded also by the European Union’s 
Seventh Program for research, technological development and demonstration under Grant 
Agreement No 269912—EPI-CT. 
Acknowledgements 
Page 36 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
The authors are grateful to the radiologists, clinicians, physicists and administrators of 
participating hospitals, the national registries of cancers and the national mortality and death 
causes registries that provided exposure and clinical data. They want to thank all the people 
involved in the building of the cohorts, more specifically Jane Salotti, Katharine Kirton and Richard 
Hardy for the British cohort, Hajo Zeeb and Steffen Dreger for the German cohort, and Pr Hubert 
Ducou Le Pointe, representative of the radiology departments involved in the French cohort. 
Disclaimer 
MSP and RWH are affiliated with the National Institute for Health Research Health Protection 
Research Unit (NIHR HPRU)) in Chemical and Radiation Threats and Hazards at Newcastle University 
in partnership with Public Health England (PHE). The views expressed are those of the authors and 
not necessarily those of the NHS, the NIHR, the Department of Health or Public Health England 
 
Disclosure of interests 
The authors declare no conflict of interest 
  
Page 37 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
References 
1. UNSCEAR. Report of the United Nations Scientific Committee on the Effects of Atomic Radiation. 
UNSCEAR 2008 report. Volume I. Annex A: Medical Radiation Exposures. United Nations, New 
York. 
2. Oatway WB, Jones AL, Holmes S, Watson S, Cabianca T. Ionising Radiation Exposure of the UK 
Population: 2010 Review. Public Health England (PHE). Chilton, Didcott. 
 3. UNSCEAR. Report of the United Nations Scientific Committee on the Effects of Atomic Radiation. 
UNSCEAR 2013 report. Volume II. Scientific Annex B - Effects of radiation exposure of children. 
United Nations, New York. 
4. Boice JD Jr, Preston D, Davis FG, Monson RR. Frequent chest X-ray fluoroscopy and breast cancer 
incidence among tuberculosis patients in Massachusetts. Radiat Res. 1991; 125:214-222. 
5. Doody M M, Lonstein JE, Stovall M, et al. Breast cancer mortality following diagnostic x-rays: 
findings from the US Scoliosis cohort study. Spine. 2000; 25:2052-63. 
6. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and 
subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012; 
380:499-505. 
7. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680 000 people exposed to computed 
tomography scans in childhood or adolescence: data linkage study of 11 million Australians. 
BMJ.2013; 346:f2360. 
8. Huang WY, Muo CH, Lin CY, et al. Paediatric head CT scan and subsequent risk of malignancy and 
benign brain tumor : a nation-wide population-based cohort study. Br J Cancer. 
2014;110:2354-60. 
9. Krille L, Dreger S, Schindel R, et al. Risk of cancer incidence before the age of 15 after exposure to 
ionizing radiation from computed tomography : results from a german cohort study. Radiat 
Environ Biophys. 2015; 2015;54:1-12. 
10. Journy N, Rehel JL, Ducou Le Pointe H, et al. Are the studies on cancer risk from CT scans biased 
by indication? Elements of answer from a large-scale cohort study in France. Br J Cancer 2015; 
112:185-93.  
11. Journy N, Roué T, Cardis E, et al. Childhood CT scans and cancer risk: impact of predisposing 
factors for cancer on the risk estimates. J Radiol Prot. 2016; 36:N1-7. 
12. Meulepas JM, Ronckers CM, Smets AM, et al. Radiation exposure from pediatric CT scans and 
subsequent cancer risk in the Netherlands. J Natl Cancer Inst. 2018. DOI:10.1093/jnci/djy104. 
(Epub ahead of print) . 
13. Boice JD, Jr. Radiation epidemiology and recent paediatric computed tomography studies. Ann 
ICRP. 2015;44:236-48.. 
Page 38 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
14. Walsh L, Shore R, Auvinen A, et al. Risks from CT scans-what do recent studies tell us? J Radiol 
Prot. 2014; E1-E5. 
15. Bosch de Basea M, Pearce MS, Kesminiene A, et al. EPI-CT: design, challenges and epidemiological 
methods of an international study on cancer risk after paediatric and young adult CT. J Radiol 
Prot. 2015; 35:611-628. 
16. Thierry-Chef I, Dabin J, Friberg EG, et al. Assessing organ doses from paediatric CT scans--a novel 
approach for an epidemiology study (the EPI-CT study). Int J Environ Res Public Health. 2013; 
10:717–28.  
17. Vandevoorde C, Gomolka M, Roessler U, et al. EPI-CT: in vitro assessment of the applicability of 
the γ-H2AX-foci assay as cellular biomarker for exposure in a multicentre study of children in 
diagnostic radiology. Int J Radiat Biol. 2015;91:653-63. 
18. Krille L, Zeeb H, Jahnen A, et al. Computed tomographies and cancer risk in children: a literature 
overview of CT practices, risk estimations and an epidemiologic cohort study proposal. Radiat 
Environ Biophys. 2012; 51:103-11. 
19. Jahnen A, Kohler S, Hermen J, et al. Automatic computed tomography patient dose calculation 
using DICOM header metadata. Radiat Prot Dosimetry. 2011;147:317-20. 
20. Lee C, Kim KP, Long DJ, Bolch WE. Organ doses for reference pediatric and adolescent patients 
undergoing computed tomography estimated by Monte Carlo simulation. Med Phys. 2012; 
39:2129-2146. 
21. Berrington de Gonzalez A, Salotti JA, McHugh K,et al. Relationship between paediatric CT scans 
and subsequent risk of leukaemia and brain tumours: assessment of the impact of underlying 
conditions. Br J Cancer. 2016; 4:388-394.  
22. Berrington de Gonzalez A, Journy N, Lee C, et al. No association between radiation dose from 
pediatric CT scans and risk of subsequent Hodgkin lymphoma. Cancer Epidemiol Biomarkers 
Prev. 2017;26:804-806. 
23. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer 
susceptibility syndromes - second edition. J Natl Cancer Inst Monogr. 2008; 38:1-93. 
24. Meulepas JM, Ronckers CM, Merks J, et al. Confounding of the association between radiation 
exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility 
syndromes. J Radiol Prot. 2016;36:953-974. 
Page 39 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
 
 
 
Page 40 of 47
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
Table 1: Description of the selection criteria and available data in the participating countries 
 Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Age range of patients at inclusion 0-18 0-18 0-9 0-14 0-17 0-20 0- 20 0-17 0-21 0-21 
Number of eligible patients at 
national level (1) 
14,002 21,649 121,101 63,998 158,130 80,225 171,336 128,748 410,997 1,170,186 
Exclusion  criteria 
          
   Inconsistent/incomplete data* 404 12 
     
4 111 531 
   Out of age range 
 
517 
   
15 
 
164 34 730 
   No CT scan in the follow-up 
period 
2,083 507 7 5,222 78 286 11,778 2,223 4,697 26,881 
   No cancer follow up 
      
60,860** 
 
51,837 112,697 
   Follow-up less than 1 year 1,074 1,666 1,611 6,607 3,962 1,103 12,072 1,564 16,973 46,632 
   Cancer diagnosed within 1 year   
after 1st CT scan 
367 1,251 84
 ±
 5,073 5,955 1,569 2,034 2,988 15,220 34,541 
Number of patients included in 
the international cohort (2) 
10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
(1)Initial number of patients included (before application of exclusion criteria); (2) Final number of eligible patients.*errors in date of birth, unknown date of cancer diagnosis; **in progress; 
 ±
 exclusion of 
patients with diagnostic of cancer within the first 6 months of follow-up at national level before sending the data for the pooled analysis. 
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Table2:  Distribution of study subjects by sex, country and age at the first CT examination  
Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Sex N (%) 
          
Male 
5,292 
(52.5) 
9,836 
(55.6) 
69,544 
(58.2) 
27,617 
(58.6) 
79,897 
(53.9) 
42,452 
(55.0) 
47,813 
(56.5) 
66,773 
(54.8) 
180,953 
(56.4 ) 
530,177 
(55.9) 
           
Female 
4,782 
(47.5) 
7,860 
(44.4) 
49,855 
(41.8) 
19,428 
(41.3) 
68,218 
(46.1) 
34,800 
(45.0) 
36,779 
(43.5) 
55,032 
(45.2) 
139,680 
(43.6) 
416,434 
(43.8) 
           
Unknown 
   
51 
(0.1) 
20 
(0)    
1,492 
(0.5) 
1,563 
(0.2) 
Median (mean) age, in years, at first examination 
     
Median 
(mean) 
11.5 
(10.4) 
12.9 
(11.3) 
2.9 
(3.5) 
6.8 
(6.8) 
11.5 
(10.3) 
14.5 
(12.8) 
13.5 
(12.0) 
11.3 
(10.3) 
13.5 
(12.0) 
10.7 
(10.2) 
Age at first CT examination N (%) 
       
<1 year 
831 
(8.2) 
1,340 
(7.6) 
34,732 
(29.1) 
5,590 
(11.9) 
13,752            
(9.3) 
4,118 
(5.3) 
6,377 
(7.5) 
9,723 
(8.0) 
32,873 
(10.2) 
109,33 
(11.5) 
           
1-4 years 
1,717 
(17.0) 
2,262 
(12.8) 
47,056 
(39.4) 
12,938 
(27.5) 
21,034 
(14.2) 
7,291 
(9.4) 
10,949 
(12.9) 
15,754 
(12.9) 
42,128 
(13.1) 
161,129 
(17.0) 
           
5-9 years 
1,824 
(18.1) 
2,820 
(15.9) 
37,611 
(31.5) 
14,171 
(30.1) 
28,997 
(19.6) 
11,156 
(14.4) 
13,216 
(15.6) 
26,600 
(21.8) 
43,515 
(13.5) 
179,910 
(19.0) 
           
10-19 years 
5,702 
(56.6) 
11,274 
(63.7)  
14,397 
(30.6) 
84,352 
(56.9) 
51,074 
(66.1) 
47,576 
(56.2) 
69,728 
(57.2) 
158,637 
(49.2) 
442,740 
(46.7) 
           
>= 20 years 
     
3,613 
(4.7) 
6,474 
(7.7)  
44,972 
(14.0) 
55,059 
(5.8) 
Total by 
country 
10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
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Table 3: Follow-up of the cohort 
 Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Mortality 
follow-up 
period 2001-2015 1999-2015 2000-2013  1979-2015 1980-2013 1991-2014 1977-2014 1985-2015 1977-2015 
Total of 
Person-Years 66,002 138,046 458,298 0 1,620,981 614,360 607,557 1,396,397 4,186,666 9,088,308 
Vital status  
N (%)           
Alive 
10,033 
(99.6) 
17,413 
(98.4) 
75,483 
(63.2) 
0 
(0) 
146,910 
(99.2) 
76,109 
(98.5) 
84,199 
(99.5) 
116,276 
(95.5) 
307,826 
(95.6) 
834,249 
(88.0) 
Deceased 
41 
(0.4) 
134 
(0.8) 
558 
(0.5) 
0 
(0) 
1,225 
(0.8) 
673 
(0.9) 
393 
(0.5) 
1,568 
(1.3) 
7,565 
(2.3) 
12,157 
(1.3) 
Lost to follow-
up 
0 
(0) 
149 
(0.8) 
0 
(0) 
0 
(0) 
0 
(0) 
470 
(0.6) 
0 
(0) 
3,961 
(3.3) 
6,734 
(2.1) 
11,314 
(1.2) 
Unavailable 
0 
(0) 
0 
(0) 
43,358 
(36.3) 
47,096 
(100) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
0 
(0) 
90,454 
(9.5) 
Cancer 
incidence 
follow-up 
period* 2001-2012 1999-2013 2000-2013 1980-2010 1979-2014 1980-2012 1991-2013 1977-2014 1985-2013 1977-2014 
 
Median 
(mean) age at 
end of follow-
up (years) 
16.2 
(15.1) 
18.1 
(17.1) 
9.4 
(9.3) 
14.2 
(12.2) 
20.1 
(20.4) 
21.2 
(20.8) 
18.4 
(17.3) 
21.7 
(21.7) 
24.0 
(23.6) 
19.5 
(19.5) 
Median 
duration of 
(mean)  
follow-up 4.1 5.3 5.4 4.7 8.2 6.8 4.8 10.3 11.3 7.8 
 (4.7) (5.8) (5.7) (5.4) (10.2) (7.9) (5.3) (11.4) (11.6) (9.3) 
Total of 
Person-years 47,815 102,657 685,333 252,970 1,506,728 613,390 448,475 1,393,454 3,720,888 8,771,710 
*: shorter follow-up period for cancer incidence compared to mortality follow-up period is linked to the delay of cancer registries to 
report cancer cases (availability of cancer cases 1 to 3 years after the cancer diagnosis date)     
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Table 4: Number of CT scans received by child 
Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Period with available PACS data (% of CT*) 
        
 
2001-2004 
(68) 
2005-2013 
(10) 
2003-2014 
(10) 
1995-2013  
(95) 
1991-2014  
(48) 
2000-2014 
(37) 
2000-2015 
(64) 
1998-2014 
(9) 
2000-2014  
(17) 
1991-2015  
(25) 
No of CT scans 
performed per child (%) 
          
1 CT scan 7,788 (77.3) 11,531 (65.2) 92,841 (77.8) 35,529 (75.4) 113,272 (76.5) 50,779 (65.7) 65,765 (77.7) 89,931 (73.8) 247,424 (76.8) 714,860 (75.4) 
           
2 CT scans 1,465 (14.5) 3,125 (17.7) 15,929 (13.3) 6,652 (14.1) 21,576 (14.6) 14,073 (18.2) 11,722 (13.9) 19,460 (16.0) 45,825 (14.2) 139,827 (14.7) 
           
3 CT scans 410 (4.1) 1,284 (7.3) 5,300 (4.4) 2,258 (4.8) 6,458 (4.4) 5,000 (6.5) 3,451 (4.1) 5,835 (4.8) 13,478 (4.2) 43,474 (4.6) 
           
4 CT scans+ 411 (4.1) 1,756 (9.9) 5,329 (4.5) 2,657 (5.6) 6,829 (4.6) 7,400 (9.6) 3,654 (4.3) 6,579 (5.4) 15,398 (4.8) 50,013 (5.3) 
           
Total 10,074 17,696 119,399 47,096 148,135 77,252 84,592 121,805 322,125 948,174 
*: proportion of CTs extracted from PACS of all CTs 
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Table 5 Distribution of CT scans according to age, calendar period and scanned region by  countries 
 Country Belgium Denmark France Germany Netherlands Norway Spain Sweden UK Total 
Category of age at CT scan N (%) 
0-4 years 
 
3,457 
(24.3) 
6,127 
(18.6) 
115,857 
(67.5) 
27,031 
(37.8) 
51,127 
(23.5) 
18,767 
(13.4) 
24,754 
(20.4) 
37,223 
(20.1) 
112,135 
(23.6) 
396,478 
(27.7) 
           
5-9 years 
 
2,486 
(17.5) 
5,422 
(16.4) 
55,794 
(32.5) 
22,011 
(30.8) 
42,157 
(19.4) 
17,988 
(12.9) 
18,630 
(15.4) 
37,547 
(20.2) 
66,702 
(14.0) 
268,737 
(18.8) 
           
10-14 years 
 
3,554 
(25.0) 
9,498 
(28.8) 
45 
(0) 
22,517 
(31.5) 
61,985 
(28.5) 
29,527 
(21.2) 
25,597 
(21.1) 
59,665 
(32.2) 
95,744 
(20.1) 
308,132 
(21.5) 
           
>= 15 
 
4,707 
(33.1) 
11,959 
(36.2) 
0 
 
0 
 
62,530 
(28.7) 
73,281 
(52.5) 
52,132 
(43.0) 
51,025 
(27.5) 
201,473 
(42.3) 
457,107 
(32.0) 
Number of CT scans by calendar period N (%) 
Before 1985  
0 
 
0 
 
0 
 
77 
(0.1) 
3,377 
(1.6) 
703 
(0.5) 
0 
 
1,244 
(0.7) 
0 
 
5,401 
(0.4) 
           
1985-1999  
0 
 
11 
(0) 
0 
 
15,414 
(21.5) 
45,539 
(20.9) 
18,843 
(13.5) 
2,236 
(1.8) 
48,905 
(26.4) 
177,118 
(37.2) 
308,066 
(21.5) 
           
2000-2009  
10,174 
(71.6) 
20,514 
(62.2) 
130,676 
(76.1) 
55,178 
(77.1) 
112,675 
(51.7) 
95,336 
(68.3) 
81,529 
(67.3) 
101,159 
(54.5) 
252,552 
(53.1) 
859,793 
(60.1) 
           
>=2010  
 
4,030 
(28.4) 
12,481 
(37.8) 
41,020 
(23.9) 
890 
(1.2) 
56,208 
(25.8) 
24,681 
(17.7) 
37,348 
(30.8) 
34,152 
(18.4) 
46,384 
(9.7) 
257,194 
(18.0) 
Number of CT scans by 
anatomical region N (%) 
Head and 
neck 
10,248 
(72.1) 
16,332 
(49.5) 
117,458 
(68.4) 
50,854 
(71.1) 
152,690 
(70.1) 
80,562 
(57.7) 
77,082 
(63.6) 
118,684 
(64.0) 
319,430 
(67.1) 
943,340 
(65.9) 
           
Chest 
1,298 
(9.1) 
4,342 
(13.2) 
33,108 
(19.3) 
8,225 
(11.5) 
18,543 
(8.5) 
19,132 
(13.7) 
11,148 
(9.2) 
15,529 
(8.4) 
40,244 
(8.5) 
151,569 
(10.6) 
           
Abdomen and 1,820 5,356 8,329 4,042 21,231 27,396 5,965 31,130 45,037 150,306 
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pelvis (%) (12.8) (16.2) (4.9) (5.6) (9.7) (19.6) (4.9) (16.8) (9.5) (10.5) 
           
Extremities 
(%) 
664 
(4.7) 
3,364 
(10.2) 
2,590 
(1.5) 
2,589 
(3.6) 
16,719 
(7.7) 
9,784 
(7.0) 
6,379 
(5.3) 
8,221 
(4.4) 
23,160 
(4.9) 
73,470 
(5.1) 
           
Multiple 
(%) 
139 
(1.0) 
3,269 
(9.9) 
8,592 
(5.0) 
3,716 
(5.2) 
5,880 
(2.7) 
2,342 
(1.7) 
8,166 
(6.7) 
7,559 
(4.1) 
30,184 
(6.3) 
69,847 
(4.9) 
Not classified 
35 
(0.2) 
343 
(1.0) 
1,619 
(0.9) 
2,133 
(3.0) 
2,736 
(1.3) 
347 
(0.2) 
12,373 
(10.2) 
4,337 
(2.3) 
17,999 
(3.8) 
41,922 
(2.9) 
Total 14,204 33,006 171,696 71,559 217,799 139,563 121,113 185,460 476,054 1,430,454 
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Table 6: SMRS of all cause, cancer and non-cancer mortality according to the time since the first CT (< 5 years; >= 5 years) 
  Time since first CT scan recorded 
 
1-5 yrs   > 5 yrs 
  
All causes 
mortality 
All cancer  
mortality 
Non cancer 
mortality  
All causes  
mortality 
All cancer  
mortality 
Non cancer  
mortality 
 
PY O  SMR (95% CI) O  SMR (95% CI) O  SMR (95% CI) PY O  SMR (95% CI) O  SMR (95% CI) O  SMR (95% CI) 
Belgium 48,125  26 1.9 (1.2,2.8)   -   - 53,387 22 1.4 (0.9,2.2)   -   - 
Denmark   84,443 101 4.9 (4.0,5.9)  - - 120,984 73 2.4 (1.9,3.1) - - 
France 322,247 474 4.9 (4.4,5.3) 25 3.5 (2.3,5.1) 357 4.0 (3.6,4.4)  349,971 120  1.6 (1.3,1.9) 6 0.8 (0.3,1.6) 79 1.1 (0.9,1.4) 
Netherlands  
693,933  692 3.7 (3.4,3.9) - - 
 
1,507,572 580  1.2 (1.1,1.3) 
 
- 
 
- 
Norway  334,723 332 2.8 (2.5,3.1) 14 1.3 (0.7,2.2) 296 2.7 (2.4,3.0)  535,107 416  1.8 (1.6,2.0) 28 1.1 (0.7,1.5) 331 1.6 (1.5,1.8) 
Spain 391,219 361 3.4 (3.1,3.8) 89 6.1 (4.9,7.5) 272 3.0 (2.6,3.4) 521,598 167  1.1 (1.0,1.3) 19 0.9 (0.5,1.3) 148 1.2 (1.0,1.4) 
Sweden 
 573,367 506 3.3 (3.0,3.6) 
58 
3.3 (2.5,4.3) 446 3.3 (3.0,3.6) 
 
1,318,489 1062 2.3 (2.2,2.4) 85 
1.3 (1.1,1.7) 
975 2.4 (2.3,2.6) 
UK 1,563,679 3068 4.9 (4.8,5.1) 177 3.0 (2.5,3.4) 2286 4.1 (3.9,4.3) 4,059,802 5,233  2.7 (2.6,2.7) 326 1.1 (1.0,1.2) 4200 2.5 (2.4,2.6) 
Pooled 4,011,736 5560 4.2 (4.1,4.3) 363 3.3 (3.0,3.7) 3657 3.7 (3.6,3.8) 8,466,910 7,673 2.2 (2.2,2.3) 464 1.1 (1.0,1.2) 5733 2.3 (2.3,2.4) 
PYs: Person-Years of follow-up; O: observed cases within the cohort; SMR: Standardized Mortality Ratio; 95% CI: 95% Confidence Interval. -: cause of death unknown; 
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Table 7: Results from EPI-CT national cohorts   
Outcome Country Cases Risk estimates (IC 95%) 
      CNS tumour risk according 
to the brain dose     
 
UK
±
 (Pearce et al, 2012) 135* ERR per mGy 0.023 (0.010,0.049) 
 
UK
±
  (Berrington et al, 2016) 122* without PF ERR per mGy 0.019 (0.008,0.043) 
 
France (Journy et al, 2015) 22 ERR per mGy 0.022  (-0.016,0.061) 
 
The Netherlands (Meulepas et al, 2018) 84 ERR per mGy 0.0086 (0.0020,0.022) 
 
Germany (Krille et al, 2015) 7 HR per mGy 1.008 (1.00,1.01) 
     
 
France (Journy et al, 2016) 15 without PF HR per 10 mGy  1.07 (0.99,1.10) 
  
7 with PF HR per 10 mGy 0.8 (0.45,1.06) 
 
UK
±
  (Pearce et al, 2012) 135* RR [50-74 mGy] vs < 5 mGy 2.82 
(1.34,6.03) 
     
Leukaemia risk according 
to RBM dose     
 
UK
±
  (Pearce et al, 2012) 74 ERR per mGy (RBM dose) 0.036 (0.005,0.120) 
 
France (Journy et al, 2015) 17 ERR per mGy 0.057 (-0.079,0.193) 
 
The Netherlands (Meulepas et al, 2018) 44 ERR per mGy 0.0004 (-0.0012,0.016) 
 
UK
±
  (Berrington et al, 2016) 70 without PF ERR per mGy 0.037 (0.005,0.126) 
     
 
France (Journy et al, 2016) 12 without PF HR per 10 mGy 1.16 (0.77-1.27) 
France (Journy et al, 2016) 5 with PF HR per 10 mGy 0.57 (0.06,1.32) 
 
Germany (Krille et al, 2015) 17 HR per mGy 1.009 (0.98,1.04) 
 
UK (Pearce et al, 2012) 74 RR [>30 mGy] vs < 5 mGy 3.18 
(1.46,6.94) 
     
 Lymphoma risk according 
to RBM dose 
 
France (Journy et al, 2015) 19 ERR per mGy 0.018 (-0.068,0.104) 
  UK
±
  (Berrington et al, 2017) 65** RR [> 20] vs <5 mGy 0.92 (0.22,2.94) 
CNS: Central Nervous System; PF: predisposing factor to CNS tumor or leukaemia, accordingly; RBM: Red Bone Marrow; ERR: Excess Relative Risk; RR: Relative Risk; HR: Hazard Ratio; mGy: milligray;  
UK: United Kingdom; * Exclusion period 5 years instead of 2 years; **: Hodgkin lymphoma only;
 ±: 
follow-up period until 2005 only. 
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